Cerebral palsy occurs in three to four infants per 1000 live births. Preterm birth prior to 34
weeks' gestation is a major risk factor. Five randomized controlled trials of antenatal …

The editors of the Journal and the SMFM Publication Committee are pleased to provide this
summary of a debate conducted at the 31st annual meeting of the Society for Maternal–Fetal …

Objective To evaluate whether magnesium sulphate (MgSO (4)) given to women at risk of
very-preterm birth would be neuroprotective in preterm newborns. Patients and methods In …

Background Epidemiological and basic science evidence suggests that magnesium
sulphate before birth may be neuroprotective for the fetus. Objectives To assess the effects …

Objective To study the effect of antenatal magnesium sulphate (MgSO4) on cerebral palsy
(CP) in a manner that also provides adequate power for a linked trial sequential analysis …

Purpose To review the effect of intravenous magnesium in obstetrics on fetal/neonatal
neuroprotection. Methods A systematic review of published studies. Results Five …

Background The aim of this study was to assess the cost-effectiveness of administering
magnesium sulphate to patients in whom preterm birth at< 32+ 0 weeks gestation is either …

Abstract Introduction Antenatal magnesium sulphate (MgSO 4) administration has shown to
be effective in minimising cerebral palsy and severe motor dysfunction at the age of 2 years …

In utero exposure to magnesium sulfate before early preterm birth appears to decrease the
incidence and severity of cerebral palsy. Cerebral palsy is the leading cause of neurologic …

Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …